Galectin Therapeutics Q3 2026 Net Loss Applicable to Common Stockholders Narrows 56% to $3.6 Million Versus Quarter Ended June 30, 2025
Galectin Therapeutics Q3 2026 Net Loss Applicable to Common Stockholders Narrows 56% to $3.6 Million
Galectin Therapeutics Q3 2026 Net Loss Applicable to Common Stockholders Narrows 56% to $3.6 Million